US1101221083 - Common Stock
BRISTOL-MYERS SQUIBB CO
NYSE:BMY (4/25/2024, 5:16:54 PM)
After market: 44.84 +0.14 (+0.31%)44.7
-4.16 (-8.51%)
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,300 full-time employees. The firm is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. The company offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. The company also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY 10016
P: 16092524621
CEO: Giovanni Caforio
Employees: 34300
Website: https://www.bms.com/
Get insights into the S&P500 index performance on Thursday. Explore the top gainers and losers within the S&P500 index in today's session.
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Thursday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Palantir stock is slipping on Thursday even as PLTR traders learn of a new contract between the data company and Parexel.
Investors didn't like the biopharmaceutical company's updated guidance.
Here you can normally see the latest stock twits on BMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: